BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

6/3/24 8:29:16 AM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BCTX alert in real time by email

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature
Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients
Therapy well-tolerated with no Bria-IMT™ related discontinuations
Clinical data highlight significant potential of Bria-IMT™ in advanced metastatic breast cancer
Superiority of selected Phase 3 regimen and formulation confirmed
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD, on Monday June 3; 11:30 AM-1:00 PM CDT

Get the next $BCTX alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$BCTX

Date	Price Target	Rating	Analyst
2/14/2022	$25.00	Buy	HC Wainwright & Co.

More analyst ratings

$BCTX
Press Releases

Fastest customizable press release news feed in the world

View All

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, releases new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvem

1/28/26 7:30:00 AM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchma

1/27/26 7:30:00 AM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or one pre-funded warrant ("Pre-Funded Warrant") in lieu thereof) and one warrant (the "Warrants"). Each unit was sold to the public at a price of US$5.59 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately US$30 million, before deduct

1/15/26 4:05:00 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

$BCTX
Leadership Updates

Live Leadership Updates

View All

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

2/5/25 6:15:47 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

1/3/25 5:05:00 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp

12/17/24 4:05:59 PM ET

$BCTX

Biotechnology: Pharmaceutical Preparations

Health Care

BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$BCTX

BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$BCTX

$BCTX
Press Releases

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

$BCTX
Analyst Ratings

HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

$BCTX
SEC Filings

SEC Form DEF 14A filed by BriaCell Therapeutics Corp.

SEC Form SCHEDULE 13G filed by BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

$BCTX
Insider Purchases

$BCTX
Insider Trading

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

SEC Form 4 filed by Williams William V.

$BCTX
Financials

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

$BCTX
Leadership Updates

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

$BCTX
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $BCTX

BriaCell Presents Clinical Efficacy Data Of Randomized Phase 2 Study Evaluating Bria-IMT In Patients With Advanced Metastatic Breast Cancer At ASCO 2024

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $BCTX

$BCTX Press Releases

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

$BCTX Analyst Ratings

HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

$BCTX SEC Filings

SEC Form DEF 14A filed by BriaCell Therapeutics Corp.

SEC Form SCHEDULE 13G filed by BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

$BCTX Insider Purchases

$BCTX Insider Trading

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

SEC Form 4 filed by Williams William V.

$BCTX Financials

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

$BCTX Leadership Updates

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

$BCTX Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

Recent Analyst Ratings for
$BCTX

Recent Analyst Ratings for
$BCTX

$BCTX
Press Releases

$BCTX
Analyst Ratings

$BCTX
SEC Filings

$BCTX
Insider Purchases

$BCTX
Insider Trading

$BCTX
Financials

$BCTX
Leadership Updates

$BCTX
Large Ownership Changes